학술논문
Sabatolimab plus hypomethylating agents in previously untreated patients with higher-risk myelodysplastic syndromes (STIMULUS-MDS1): a randomised, double-blind, placebo-controlled, phase 2 trial
Document Type
Article
Author
Zeidan, Amer M ; Ando, Kiyoshi; Rauzy, Odile; Turgut, Mehmet; Wang, Ming-Chung; Cairoli, Roberto; Hou, Hsin-An; Kwong, Yok-Lam; Arnan, Montserrat; Meers, Stef; Pullarkat, Vinod; Santini, Valeria; Malek, Kamel; Kiertsman, Flavia; Niolat, Julie; Ramos, Pedro Marques; Menssen, Hans D; Fenaux, Pierre; Miyazaki, Yasushi; Platzbecker, Uwe
Source
In The Lancet Haematology January 2024 11(1):e38-e50
Subject
Language
ISSN
2352-3026